{
  "041.SG": {
    "city": "CÃ¡diz",
    "country": "Spain",
    "currency": "EUR",
    "exchange": "STU",
    "industry": "Biotechnology",
    "long_name": "ADL Bionatur Solutions, S.A.",
    "market": "dr_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "ADL Bionatur Solutions S.A. Acc",
    "state": null,
    "summary": "ADL Bionatur Solutions, S.A. engages in the research, development, manufacturing, and commercialization of products in biotech and pharmaceutical industry in Spain. It provides solutions in health, nutrition, cosmetics, and materials. The company was founded in 1954 and is headquartered in CÃ¡diz, Spain.",
    "website": "http://www.adlbionatur.com",
    "zipcode": "11591"
  },
  "41L.F": {
    "city": "Madrid",
    "country": "Spain",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Biotechnology",
    "long_name": "Laboratorios Farmaceuticos Rovi, S.A.",
    "market": "dr_market",
    "market_cap": "Mid Cap",
    "sector": "Healthcare",
    "short_name": "LABORATORIOS FARMACEUT.",
    "state": null,
    "summary": "Laboratorios Farmaceuticos Rovi, S.A. engages in the research, development, production, and sale of pharmaceutical products in Spain, European Union, OECD countries, and internationally. The company distributes other products that are licensed from other laboratories. Its principal products include Hibor, a low-molecular-weight heparin to prevent and treat venous thromboembolic disease; Enoxaparin biosimilar Becat, a low-molecular-weight heparin; Neparvis to treat symptomatic chronic heart failure with reduced ejection in adult patients; Absorcol, Vytorin, and Orvatez to diet in patients with hypercholesterolemia; Hirobriz Breezhaler and Ulunar Breezhaler that are long-acting bronchodilators for the maintenance treatment of chronic obstructive pulmonary diseases; Volutsa for treatment of moderate to severe storage systems symptoms and voiding symptoms associated with benign prostatic hyperplasia in men who are not responding adequately to monotherapy treatment; and Medikinet and MedicebrÃ¡n to treat attention deficit hyperactivity disorder in children and teenagers. The company also markets various hospital products for imaging diagnosis, such as Iomeron and Iopamiro for computed tomography and intervention; Multihance and Prohance for magnetic resonance imaging; Sonovue for ultrasounds; and EmpowerCTA+, EmpowerMR, and CT ExprÃ¨s that are contrast injection systems and compatible disposable material. It provides non-prescription pharmaceutical products; and contract-manufacturing services to other companies for a range of pharmaceutical forms, including prefilled syringes, vials, suppositories, tablets, hard capsules, and sachets. The company serves wholesalers, doctors, nursing staff, pharmacists, and patients. It has a collaboration with Moderna, Inc. for manufacturing mRNA COVID-19 vaccine candidate. The company was incorporated in 1946 and is headquartered in Madrid, Spain. Laboratorios FarmaceÃºticos Rovi, S.A. is a subsidiary of Norbel Inversiones, S.L.",
    "website": "http://www.rovi.es",
    "zipcode": "28223"
  },
  "ADL.MC": {
    "city": "CÃ¡diz",
    "country": "Spain",
    "currency": "EUR",
    "exchange": "MCE",
    "industry": "Biotechnology",
    "long_name": "ADL Bionatur Solutions, S.A.",
    "market": "es_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "ADL BIONATUR SOLUTIONS, S.A.",
    "state": null,
    "summary": "ADL Bionatur Solutions, S.A. engages in the research, development, manufacturing, and commercialization of products in biotech and pharmaceutical industry in Spain. It provides solutions in health, nutrition, cosmetics, and materials. The company was founded in 1954 and is headquartered in CÃ¡diz, Spain.",
    "website": "http://www.adlbionatur.com",
    "zipcode": "11591"
  },
  "ALM.MC": {
    "city": "Barcelona",
    "country": "Spain",
    "currency": "EUR",
    "exchange": "MCE",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "Almirall, S.A.",
    "market": "es_market",
    "market_cap": "Mid Cap",
    "sector": "Healthcare",
    "short_name": "ALMIRALL S.A.",
    "state": null,
    "summary": "Almirall, S.A., a pharmaceutical company, engages in the research, development, manufacture, and sale of skin-health related medicines worldwide. The company offers its products for dermatological diseases comprising actinic keratosis, atopic dermatitis, cutaneous T-cell lymphoma, androgenic alopecia, psoriasis, onychomycosis, oncodermatology, acne, and orphan indications; and for central nervous system, cardiovascular, and gastrointestinal diseases. Its products include Actikerall, Solaraze, Cordran Tape, Skilarence, Ilumetri, Seysara, Almax, Crestor, Provisacor, Sativex, Ebastel, Aczone, Tazorac, Azelex, and Veltin. Almirall, S.A. has a strategic research collaboration with Evotec AG to discover and develop first-in-class therapeutics in the field of dermatology diseases; collaborative research and license agreement with X-Chem, Inc. for the development of oral compounds for patients suffering from dermatological diseases; research collaboration with Iktos in the area of artificial intelligence for new drug design; multi-target research collaboration with the University of Dundee to develop novel targeted protein degraders medicines; and collaboration with Popit to provide a novel support solution for patients with psoriasis. It also has a strategic partnership with Tyris Therapeutics to develop gene therapies for the treatment of rare genetic dermatology diseases; and Happify Health to develop evidence-supported digital therapeutics solutions for psoriasis patients. The company was formerly known as Laboratorios Almirall, S.A. and changed its name to Almirall, S.A. in May 2009. Almirall, S.A. was founded in 1943 and is headquartered in Barcelona, Spain.",
    "website": "http://www.almirall.com",
    "zipcode": "08022"
  },
  "ATRY.MC": {
    "city": "Barcelona",
    "country": "Spain",
    "currency": "EUR",
    "exchange": "MCE",
    "industry": "Biotechnology",
    "long_name": "Atrys Health, S.A.",
    "market": "es_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "ATRYS HEALTH, S.A.",
    "state": null,
    "summary": "Atrys Health, S.A., a biomedical company, provides diagnostic services and medical treatments. The company offers diagnostic services in the fields of pathology, hematology, molecular pathology, and genetics; and diagnostic second opinion, test directory, and clinical trials and R&D services. It uses telemedicine to provide its services in the medical specialties of radiology, cardiology, ophthalmology, and dermatology. The company also provides radiotherapy; and develops therapeutic modalities and diagnostic tools. Atrys Health, S.A. was founded in 2007 and is based in Barcelona, Spain.",
    "website": "http://www.atryshealth.com",
    "zipcode": "08025"
  },
  "BIO.MC": {
    "city": "Granada",
    "country": "Spain",
    "currency": "EUR",
    "exchange": "MCE",
    "industry": "Biotechnology",
    "long_name": "Biosearch, S.A.",
    "market": "es_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "BIOSEARCH, S.A.",
    "state": null,
    "summary": "Biosearch, S.A., a biotechnology company, operates in pharmaceutical, nutraceutical, and functional food sectors worldwide. It offers a portfolio of approximately 200 products in lipids, probiotics, and botanical extracts. The company provides a range of probiotics isolated from human breast milk under the Hereditum brand for use in infant nutrition, gastrointestinal health, and immune system and prevention of infections. It also offers various eicosapentaenoic acid and docosahexaenoic acid rich ingredients under the Eupoly-3 name, which consists of oils, emulsions, and micro-encapsulated powder for functional foods, primarily dairy products, baby foods, medical foods, and food supplements. In addition, the company provides dry, fluid, glycerinated, and soft extracts under the Exxentia name. Biosearch, S.A. is headquartered in Granada, Spain.",
    "website": "http://www.biosearchlife.es",
    "zipcode": "18004"
  },
  "CBAV.MC": {
    "city": "Madrid",
    "country": "Spain",
    "currency": "EUR",
    "exchange": "MCE",
    "industry": "Diagnostics & Research",
    "long_name": "Clínica Baviera, S.A.",
    "market": "es_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "CLINICA BAVIERA S.A.",
    "state": null,
    "summary": "ClÃ­nica Baviera, S.A. operates a network of ophthalmological clinics. It is involved in the diagnosis, treatment, and monitoring of various types of ophthalmological disorders. The company's clinics offers myopia, hyperopia, astigmatism, presbyopia, cataract, retina, pediatric ophthalmology, glaucoma, squint, oculoplasty, cornea, neuroftalmologÃ­a, and vias lagrimales treatments, as well as refractive surgery services. It operates approximately 80 ophthalmological clinics in Spain, Germany, Austria, and Italy. The company is based in Madrid, Spain.",
    "website": "http://www.clinicabaviera.com",
    "zipcode": "28046"
  },
  "D9Z.F": {
    "city": "Madrid",
    "country": "Spain",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Diagnostics & Research",
    "long_name": "Clínica Baviera, S.A.",
    "market": "dr_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "CLINICA BAVIERA SA EO-,10",
    "state": null,
    "summary": "ClÃ­nica Baviera, S.A. operates a network of ophthalmological clinics. It is involved in the diagnosis, treatment, and monitoring of various types of ophthalmological disorders. The company's clinics offers myopia, hyperopia, astigmatism, presbyopia, cataract, retina, pediatric ophthalmology, glaucoma, squint, oculoplasty, cornea, neuroftalmologÃ­a, and vias lagrimales treatments, as well as refractive surgery services. It operates approximately 80 ophthalmological clinics in Spain, Germany, Austria, and Italy. The company is based in Madrid, Spain.",
    "website": "http://www.clinicabaviera.com",
    "zipcode": "28046"
  },
  "E2Z.F": {
    "city": "Barcelona",
    "country": "Spain",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "Almirall, S.A.",
    "market": "dr_market",
    "market_cap": "Mid Cap",
    "sector": "Healthcare",
    "short_name": "ALMIRALL S.A.  EO -,12",
    "state": null,
    "summary": "Almirall, S.A., a pharmaceutical company, engages in the research, development, manufacture, and sale of skin-health related medicines worldwide. The company offers its products for dermatological diseases comprising actinic keratosis, atopic dermatitis, cutaneous T-cell lymphoma, androgenic alopecia, psoriasis, onychomycosis, oncodermatology, acne, and orphan indications; and for central nervous system, cardiovascular, and gastrointestinal diseases. Its products include Actikerall, Solaraze, Cordran Tape, Skilarence, Ilumetri, Seysara, Almax, Crestor, Provisacor, Sativex, Ebastel, Aczone, Tazorac, Azelex, and Veltin. Almirall, S.A. has a strategic research collaboration with Evotec AG to discover and develop first-in-class therapeutics in the field of dermatology diseases; collaborative research and license agreement with X-Chem, Inc. for the development of oral compounds for patients suffering from dermatological diseases; research collaboration with Iktos in the area of artificial intelligence for new drug design; multi-target research collaboration with the University of Dundee to develop novel targeted protein degraders medicines; and collaboration with Popit to provide a novel support solution for patients with psoriasis. It also has a strategic partnership with Tyris Therapeutics to develop gene therapies for the treatment of rare genetic dermatology diseases; and Happify Health to develop evidence-supported digital therapeutics solutions for psoriasis patients. The company was formerly known as Laboratorios Almirall, S.A. and changed its name to Almirall, S.A. in May 2009. Almirall, S.A. was founded in 1943 and is headquartered in Barcelona, Spain.",
    "website": "http://www.almirall.com",
    "zipcode": "08022"
  },
  "EEP.MC": {
    "city": "Corunna",
    "country": "Spain",
    "currency": "EUR",
    "exchange": "MCE",
    "industry": "Diagnostics & Research",
    "long_name": "Euroespes, S.A.",
    "market": "es_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "EUROESPES, S.A.",
    "state": null,
    "summary": "Euroespes, S.A., a medical center, provides medical services for the research, diagnosis, and treatment of central nervous system disorders and other diseases in Spain and internationally. It offers personalized and genomic medicine services for predictive, diagnostic, and therapeutic purposes. The company also provides medical services, such as digital diagnosis, neuro-psychology, neuro-otolaryngology, neuro-ophthalmology, nursing, radioa diagnosis, and laboratory services. In addition, it offers pharmacogenetic cards; biotechnology; and a range of nutraceuticals. The company was founded in 1991 and is based in Corunna, Spain.",
    "website": "http://www.euroespes.com",
    "zipcode": "15165"
  },
  "FAE.MC": {
    "city": "Leioa",
    "country": "Spain",
    "currency": "EUR",
    "exchange": "MCE",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "Faes Farma, S.A.",
    "market": "es_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "FAES FARMA, S.A.",
    "state": null,
    "summary": "Faes Farma, S.A., a pharmaceutical company, researches, develops, produces, and commercializes pharmaceutical products and raw materials in Spain and internationally. The company's product portfolio includes prescription drugs, generic drugs, over-the-counter (OTC) drugs, food supplements, baby foods, and other health products. It offers Actimag, a magnesium pidolate; Bilaxten, an anti-allergic; Bronquidiazina CR, an anti-infective; Claversal for ulcerative colitis and Crohn's disease; Dezacor, a corticoid; Dolotren, an anti-inflammatory; Dolotren Gel; Dynamogen, an anti-anorexic; Ferroprotina, an anti-anaemic; Hidroferol; Lipofen; Positon for dermatitis; strength builder products, such as Potenciator and Surmenalit; Pruina, a laxative; Robaxisal Compuesto, a muscle relaxant and analgesic; Trausan, a citicoline; Venosmil, a venous vasoprotector; Venosmil Gel; and Yendol, an anti-flu. The company also provides Bilastine, an antihistamine molecule for the treatment of allergic rhino conjunctivitis and urticarial; Calcifediol for bone metabolism; Deflazacort to treat osteoarticular disease; Hidrosmin for venous insufficiency; and Mesalazine to treat digestion problems. It also exports its products. Faes Farma, S.A. was founded in 1933 and is headquartered in Leioa, Spain.",
    "website": "http://faesfarma.com",
    "zipcode": "48940"
  },
  "FEQ1.F": {
    "city": "Barcelona",
    "country": "Spain",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "Laboratorio Reig Jofre, S.A.",
    "market": "dr_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "LABORATORIO REIG J.EO 0,5",
    "state": null,
    "summary": "Laboratorio Reig Jofre, S.A., a pharmaceutical company, researches, develops, manufactures, and markets pharmaceutical products and food supplements. The company offers prescription medicines, OTCs, medical devices, and cosmetics. Its products include pharmaceutical technologies products, such as antibiotics, and injectable and other products; specialty pharmacare products, which include skin, hair, and nail health, joint health and pain, women's health, respiratory/ENT, and pediatrics; and consumer healthcare products under the FortÃ© Pharma brand. The company also provides CDMO and CMO services. It sells its products directly in 7 countries and through business partners in approximately 70 countries. The company was founded in 1929 and is based in Sant Joan DespÃ­, Spain. Laboratorio Reig Jofre, S.A. is a subsidiary of Reig Jofre Investments SL.",
    "website": "http://www.reigjofre.com",
    "zipcode": "08970"
  },
  "FFEA.F": {
    "city": "Leioa",
    "country": "Spain",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "Faes Farma, S.A.",
    "market": "dr_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "FAES FARMA INH.  EO-,10",
    "state": null,
    "summary": "Faes Farma, S.A., a pharmaceutical company, researches, develops, produces, and commercializes pharmaceutical products and raw materials in Spain and internationally. The company's product portfolio includes prescription drugs, generic drugs, over-the-counter (OTC) drugs, food supplements, baby foods, and other health products. It offers Actimag, a magnesium pidolate; Bilaxten, an anti-allergic; Bronquidiazina CR, an anti-infective; Claversal for ulcerative colitis and Crohn's disease; Dezacor, a corticoid; Dolotren, an anti-inflammatory; Dolotren Gel; Dynamogen, an anti-anorexic; Ferroprotina, an anti-anaemic; Hidroferol; Lipofen; Positon for dermatitis; strength builder products, such as Potenciator and Surmenalit; Pruina, a laxative; Robaxisal Compuesto, a muscle relaxant and analgesic; Trausan, a citicoline; Venosmil, a venous vasoprotector; Venosmil Gel; and Yendol, an anti-flu. The company also provides Bilastine, an antihistamine molecule for the treatment of allergic rhino conjunctivitis and urticarial; Calcifediol for bone metabolism; Deflazacort to treat osteoarticular disease; Hidrosmin for venous insufficiency; and Mesalazine to treat digestion problems. It also exports its products. Faes Farma, S.A. was founded in 1933 and is headquartered in Leioa, Spain.",
    "website": "http://faesfarma.com",
    "zipcode": "48940"
  },
  "G0FB.F": {
    "city": "Barcelona",
    "country": "Spain",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Drug Manufacturers - General",
    "long_name": "Grifols, S.A.",
    "market": "dr_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "GRIFOLS SP.ADR B EO-,10 1",
    "state": null,
    "summary": "Grifols, S.A. engages in the procurement, manufacture, preparation, and sale of therapeutic products primarily hemoderivatives. The company operates through Bioscience, Hospital, Diagnostic, Bio Supplies, and Others segments. The Bioscience segment produces plasma-derived medicines for the treatment of rare, chronic, and life-threatening conditions. It offers intravenous immunoglobin, albumin, alpha-1-antitrypsin, factor VIII, antithrombin, and other specialty hyperimmune immunoglobulins. The Hospital segment offers non-biological pharmaceutical products and medical supplies for hospital pharmacy, such as intravenous solutions, pharmatech solutions, clinical nutrition products, and medical devices for interventional therapy. The Diagnostic segment manufactures and markets diagnostic testing equipment, reagents, and other equipment. The Bio Supplies segment provides biological products for non-therapeutic uses. The Others segment renders manufacturing services to third party companies. The company also provides engineering services; and rents industrial buildings. Its products and services are used by healthcare providers to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases, and other medical conditions. The company serves public and private customers; and wholesalers, distributors, group purchasing organizations, blood banks, hospitals and care institutions, and national health systems. Grifols, S.A. has a technology collaboration agreement with Mondragon. The company was founded in 1940 and is headquartered in Barcelona, Spain.",
    "website": "http://www.grifols.com",
    "zipcode": "08174"
  },
  "GIFLF": {
    "city": "Barcelona",
    "country": "Spain",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Drug Manufacturers - General",
    "long_name": "Grifols, S.A.",
    "market": "us_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "GRIFOLS SA",
    "state": null,
    "summary": "Grifols, S.A. engages in the procurement, manufacture, preparation, and sale of therapeutic products primarily hemoderivatives. The company operates through Bioscience, Hospital, Diagnostic, Bio Supplies, and Others segments. The Bioscience segment produces plasma-derived medicines for the treatment of rare, chronic, and life-threatening conditions. It offers intravenous immunoglobin, albumin, alpha-1-antitrypsin, factor VIII, antithrombin, and other specialty hyperimmune immunoglobulins. The Hospital segment offers non-biological pharmaceutical products and medical supplies for hospital pharmacy, such as intravenous solutions, pharmatech solutions, clinical nutrition products, and medical devices for interventional therapy. The Diagnostic segment manufactures and markets diagnostic testing equipment, reagents, and other equipment. The Bio Supplies segment provides biological products for non-therapeutic uses. The Others segment renders manufacturing services to third party companies. The company also provides engineering services; and rents industrial buildings. Its products and services are used by healthcare providers to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases, and other medical conditions. The company serves public and private customers; and wholesalers, distributors, group purchasing organizations, blood banks, hospitals and care institutions, and national health systems. Grifols, S.A. has a technology collaboration agreement with Mondragon. The company was founded in 1940 and is headquartered in Barcelona, Spain.",
    "website": "http://www.grifols.com",
    "zipcode": "08174"
  },
  "GIKLY": {
    "city": "Barcelona",
    "country": "Spain",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Drug Manufacturers - General",
    "long_name": "Grifols, S.A.",
    "market": "us_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "GRIFOLS SA",
    "state": null,
    "summary": "Grifols, S.A. engages in the procurement, manufacture, preparation, and sale of therapeutic products primarily hemoderivatives. The company operates through Bioscience, Hospital, Diagnostic, Bio Supplies, and Others segments. The Bioscience segment produces plasma-derived medicines for the treatment of rare, chronic, and life-threatening conditions. It offers intravenous immunoglobin, albumin, alpha-1-antitrypsin, factor VIII, antithrombin, and other specialty hyperimmune immunoglobulins. The Hospital segment offers non-biological pharmaceutical products and medical supplies for hospital pharmacy, such as intravenous solutions, pharmatech solutions, clinical nutrition products, and medical devices for interventional therapy. The Diagnostic segment manufactures and markets diagnostic testing equipment, reagents, and other equipment. The Bio Supplies segment provides biological products for non-therapeutic uses. The Others segment renders manufacturing services to third party companies. The company also provides engineering services; and rents industrial buildings. Its products and services are used by healthcare providers to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases, and other medical conditions. The company serves public and private customers; and wholesalers, distributors, group purchasing organizations, blood banks, hospitals and care institutions, and national health systems. Grifols, S.A. has a technology collaboration agreement with Mondragon. The company was founded in 1940 and is headquartered in Barcelona, Spain.",
    "website": "http://www.grifols.com",
    "zipcode": "08174"
  },
  "GRF.MC": {
    "city": "Barcelona",
    "country": "Spain",
    "currency": "EUR",
    "exchange": "MCE",
    "industry": "Drug Manufacturers - General",
    "long_name": "Grifols, S.A.",
    "market": "es_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "GRIFOLS S.A.",
    "state": null,
    "summary": "Grifols, S.A. engages in the procurement, manufacture, preparation, and sale of therapeutic products primarily hemoderivatives. The company operates through Bioscience, Hospital, Diagnostic, Bio Supplies, and Others segments. The Bioscience segment produces plasma-derived medicines for the treatment of rare, chronic, and life-threatening conditions. It offers intravenous immunoglobin, albumin, alpha-1-antitrypsin, factor VIII, antithrombin, and other specialty hyperimmune immunoglobulins. The Hospital segment offers non-biological pharmaceutical products and medical supplies for hospital pharmacy, such as intravenous solutions, pharmatech solutions, clinical nutrition products, and medical devices for interventional therapy. The Diagnostic segment manufactures and markets diagnostic testing equipment, reagents, and other equipment. The Bio Supplies segment provides biological products for non-therapeutic uses. The Others segment renders manufacturing services to third party companies. The company also provides engineering services; and rents industrial buildings. Its products and services are used by healthcare providers to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases, and other medical conditions. The company serves public and private customers; and wholesalers, distributors, group purchasing organizations, blood banks, hospitals and care institutions, and national health systems. Grifols, S.A. has a technology collaboration agreement with Mondragon. The company was founded in 1940 and is headquartered in Barcelona, Spain.",
    "website": "http://www.grifols.com",
    "zipcode": "08174"
  },
  "GRF.VI": {
    "city": "Barcelona",
    "country": "Spain",
    "currency": "EUR",
    "exchange": "VIE",
    "industry": "Drug Manufacturers - General",
    "long_name": "Grifols, S.A.",
    "market": "at_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "GRIFOLS SA",
    "state": null,
    "summary": "Grifols, S.A. engages in the procurement, manufacture, preparation, and sale of therapeutic products primarily hemoderivatives. The company operates through Bioscience, Hospital, Diagnostic, Bio Supplies, and Others segments. The Bioscience segment produces plasma-derived medicines for the treatment of rare, chronic, and life-threatening conditions. It offers intravenous immunoglobin, albumin, alpha-1-antitrypsin, factor VIII, antithrombin, and other specialty hyperimmune immunoglobulins. The Hospital segment offers non-biological pharmaceutical products and medical supplies for hospital pharmacy, such as intravenous solutions, pharmatech solutions, clinical nutrition products, and medical devices for interventional therapy. The Diagnostic segment manufactures and markets diagnostic testing equipment, reagents, and other equipment. The Bio Supplies segment provides biological products for non-therapeutic uses. The Others segment renders manufacturing services to third party companies. The company also provides engineering services; and rents industrial buildings. Its products and services are used by healthcare providers to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases, and other medical conditions. The company serves public and private customers; and wholesalers, distributors, group purchasing organizations, blood banks, hospitals and care institutions, and national health systems. Grifols, S.A. has a technology collaboration agreement with Mondragon. The company was founded in 1940 and is headquartered in Barcelona, Spain.",
    "website": "http://www.grifols.com",
    "zipcode": "08174"
  },
  "GRFS": {
    "city": "Barcelona",
    "country": "Spain",
    "currency": "USD",
    "exchange": "NMS",
    "industry": "Drug Manufacturers - General",
    "long_name": "Grifols, S.A.",
    "market": "us_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "Grifols, S.A.",
    "state": null,
    "summary": "Grifols, S.A. engages in the procurement, manufacture, preparation, and sale of therapeutic products primarily hemoderivatives. The company operates through Bioscience, Hospital, Diagnostic, Bio Supplies, and Others segments. The Bioscience segment produces plasma-derived medicines for the treatment of rare, chronic, and life-threatening conditions. It offers intravenous immunoglobin, albumin, alpha-1-antitrypsin, factor VIII, antithrombin, and other specialty hyperimmune immunoglobulins. The Hospital segment offers non-biological pharmaceutical products and medical supplies for hospital pharmacy, such as intravenous solutions, pharmatech solutions, clinical nutrition products, and medical devices for interventional therapy. The Diagnostic segment manufactures and markets diagnostic testing equipment, reagents, and other equipment. The Bio Supplies segment provides biological products for non-therapeutic uses. The Others segment renders manufacturing services to third party companies. The company also provides engineering services; and rents industrial buildings. Its products and services are used by healthcare providers to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases, and other medical conditions. The company serves public and private customers; and wholesalers, distributors, group purchasing organizations, blood banks, hospitals and care institutions, and national health systems. Grifols, S.A. has a technology collaboration agreement with Mondragon. The company was founded in 1940 and is headquartered in Barcelona, Spain.",
    "website": "http://www.grifols.com",
    "zipcode": "08174"
  },
  "LABFF": {
    "city": "Madrid",
    "country": "Spain",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Biotechnology",
    "long_name": "Laboratorios Farmaceuticos Rovi, S.A.",
    "market": "us_market",
    "market_cap": "Mid Cap",
    "sector": "Healthcare",
    "short_name": "LABORATORIOS FARMACEUTOCOS ROVI",
    "state": null,
    "summary": "Laboratorios Farmaceuticos Rovi, S.A. engages in the research, development, production, and sale of pharmaceutical products in Spain, European Union, OECD countries, and internationally. The company distributes other products that are licensed from other laboratories. Its principal products include Hibor, a low-molecular-weight heparin to prevent and treat venous thromboembolic disease; Enoxaparin biosimilar Becat, a low-molecular-weight heparin; Neparvis to treat symptomatic chronic heart failure with reduced ejection in adult patients; Absorcol, Vytorin, and Orvatez to diet in patients with hypercholesterolemia; Hirobriz Breezhaler and Ulunar Breezhaler that are long-acting bronchodilators for the maintenance treatment of chronic obstructive pulmonary diseases; Volutsa for treatment of moderate to severe storage systems symptoms and voiding symptoms associated with benign prostatic hyperplasia in men who are not responding adequately to monotherapy treatment; and Medikinet and MedicebrÃ¡n to treat attention deficit hyperactivity disorder in children and teenagers. The company also markets various hospital products for imaging diagnosis, such as Iomeron and Iopamiro for computed tomography and intervention; Multihance and Prohance for magnetic resonance imaging; Sonovue for ultrasounds; and EmpowerCTA+, EmpowerMR, and CT ExprÃ¨s that are contrast injection systems and compatible disposable material. It provides non-prescription pharmaceutical products; and contract-manufacturing services to other companies for a range of pharmaceutical forms, including prefilled syringes, vials, suppositories, tablets, hard capsules, and sachets. The company serves wholesalers, doctors, nursing staff, pharmacists, and patients. It has a collaboration with Moderna, Inc. for manufacturing mRNA COVID-19 vaccine candidate. The company was incorporated in 1946 and is headquartered in Madrid, Spain. Laboratorios FarmaceÃºticos Rovi, S.A. is a subsidiary of Norbel Inversiones, S.L.",
    "website": "http://www.rovi.es",
    "zipcode": "28223"
  },
  "MED.MC": {
    "city": "Barcelona",
    "country": "Spain",
    "currency": "EUR",
    "exchange": "MCE",
    "industry": "Medical Distribution",
    "long_name": "Medcomtech, S.A.",
    "market": "es_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "MEDCOM TECH, S.A.",
    "state": null,
    "summary": "Medcomtech, S.A. distributes products in the areas of orthopedic surgery, traumatology, neurosurgery, and anesthesia worldwide. The company offers orthopedic surgery, trauma, and neurosurgery products for spine, hip-femur-knee, biologics, and upper and lower limbs, as well as biologics and cements. It also provides anesthesia products in the area of airway management. The company was founded in 2001 and is based in Barcelona, Spain.",
    "website": "http://www.medcomtech.es",
    "zipcode": "08840"
  },
  "ORN.F": {
    "city": "CornellÃ  de Llobregat",
    "country": "Spain",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Biotechnology",
    "long_name": "Oryzon Genomics S.A.",
    "market": "dr_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "ORYZON GENOMICS SA EO-,05",
    "state": null,
    "summary": "Oryzon Genomics S.A., a clinical phase biopharmaceutical company, engages in the discovery and development of epigenetics-based therapeutics for the treatment of oncological and CNS disorders. Its clinical phase compounds include iadademstat (ORY-1001), a selective LSD1 inhibitor that is in Phase II trials for oncology; and vafidemstat (ORY-2001), a CNS-optimized LSD1 inhibitor, which is in Phase II trials for the treatment of CNS and psychiatric diseases. Its product candidates also comprise ORY-3001, a LSD1 inhibitor that is in preclinical development for the treatment of non-oncological diseases, as well as other programs at various stages of development. The company was founded in 2000 and is based in CornellÃ  de Llobregat, Spain.",
    "website": "http://www.oryzon.com",
    "zipcode": "08940"
  },
  "ORY.MC": {
    "city": "CornellÃ  de Llobregat",
    "country": "Spain",
    "currency": "EUR",
    "exchange": "MCE",
    "industry": "Biotechnology",
    "long_name": "Oryzon Genomics S.A.",
    "market": "es_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "ORYZON GENOMICS, S.A.",
    "state": null,
    "summary": "Oryzon Genomics S.A., a clinical phase biopharmaceutical company, engages in the discovery and development of epigenetics-based therapeutics for the treatment of oncological and CNS disorders. Its clinical phase compounds include iadademstat (ORY-1001), a selective LSD1 inhibitor that is in Phase II trials for oncology; and vafidemstat (ORY-2001), a CNS-optimized LSD1 inhibitor, which is in Phase II trials for the treatment of CNS and psychiatric diseases. Its product candidates also comprise ORY-3001, a LSD1 inhibitor that is in preclinical development for the treatment of non-oncological diseases, as well as other programs at various stages of development. The company was founded in 2000 and is based in CornellÃ  de Llobregat, Spain.",
    "website": "http://www.oryzon.com",
    "zipcode": "08940"
  },
  "ORYZF": {
    "city": "CornellÃ  de Llobregat",
    "country": "Spain",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Biotechnology",
    "long_name": "Oryzon Genomics S.A.",
    "market": "us_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "ORYZON GENOMICS SA",
    "state": null,
    "summary": "Oryzon Genomics S.A., a clinical phase biopharmaceutical company, engages in the discovery and development of epigenetics-based therapeutics for the treatment of oncological and CNS disorders. Its clinical phase compounds include iadademstat (ORY-1001), a selective LSD1 inhibitor that is in Phase II trials for oncology; and vafidemstat (ORY-2001), a CNS-optimized LSD1 inhibitor, which is in Phase II trials for the treatment of CNS and psychiatric diseases. Its product candidates also comprise ORY-3001, a LSD1 inhibitor that is in preclinical development for the treatment of non-oncological diseases, as well as other programs at various stages of development. The company was founded in 2000 and is based in CornellÃ  de Llobregat, Spain.",
    "website": "http://www.oryzon.com",
    "zipcode": "08940"
  },
  "OZTA.F": {
    "city": "Barcelona",
    "country": "Spain",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Drug Manufacturers - General",
    "long_name": "Grifols, S.A.",
    "market": "dr_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "GRIFOLS SA INH. A  EO-,25",
    "state": null,
    "summary": "Grifols, S.A. engages in the procurement, manufacture, preparation, and sale of therapeutic products primarily hemoderivatives. The company operates through Bioscience, Hospital, Diagnostic, Bio Supplies, and Others segments. The Bioscience segment produces plasma-derived medicines for the treatment of rare, chronic, and life-threatening conditions. It offers intravenous immunoglobin, albumin, alpha-1-antitrypsin, factor VIII, antithrombin, and other specialty hyperimmune immunoglobulins. The Hospital segment offers non-biological pharmaceutical products and medical supplies for hospital pharmacy, such as intravenous solutions, pharmatech solutions, clinical nutrition products, and medical devices for interventional therapy. The Diagnostic segment manufactures and markets diagnostic testing equipment, reagents, and other equipment. The Bio Supplies segment provides biological products for non-therapeutic uses. The Others segment renders manufacturing services to third party companies. The company also provides engineering services; and rents industrial buildings. Its products and services are used by healthcare providers to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases, and other medical conditions. The company serves public and private customers; and wholesalers, distributors, group purchasing organizations, blood banks, hospitals and care institutions, and national health systems. Grifols, S.A. has a technology collaboration agreement with Mondragon. The company was founded in 1940 and is headquartered in Barcelona, Spain.",
    "website": "http://www.grifols.com",
    "zipcode": "08174"
  },
  "PANG.MC": {
    "city": "Barcelona",
    "country": "Spain",
    "currency": "EUR",
    "exchange": "MCE",
    "industry": "Diagnostics & Research",
    "long_name": "Pangaea Oncology, S.A.",
    "market": "es_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "PANGAEA ONCOLOGY S.A.",
    "state": null,
    "summary": "Pangaea Oncology, S.A., a medical services company, provides a range of services to cancer patients, and pharmaceutical and biotech clients worldwide. It offers molecular diagnostics, such as mutation analysis in tumor tissue and blood, gene amplification and translocation testing, immunohistochemistry, and gene expression; clinical trials; in vitro drug profiling, including MTT proliferation assays, Western blotting, colony formation, migration and invasion assays, and gene silencing; and Dx platform, which performs companion diagnostic platform validation, validation against commercially available platforms, and Ad-hoc R+D for diagnostics companies. The company also provides biomarker discovery to identify novel targets for targeted therapies in pre-clinical development. Pangaea Oncology, S.A. was founded in 2007 and is based in Barcelona, Spain.",
    "website": "http://www.panoncology.com",
    "zipcode": "08028"
  },
  "PHM.MC": {
    "city": "Madrid",
    "country": "Spain",
    "currency": "EUR",
    "exchange": "MCE",
    "industry": "Biotechnology",
    "long_name": "Pharma Mar, S.A.",
    "market": "es_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "PHARMA MAR, S.A.",
    "state": null,
    "summary": "Pharma Mar, S.A., a biopharmaceutical company, engages in the research, development, production, and commercialization of bio-active principles of marine origin for use in oncology in Spain, rest of Europe, and internationally. The company operates through three segments: Oncology, Diagnostics, and RNA interference. It develops and commercializes Yondelis for the treatment of soft tissue sarcomas and for ovarian cancer; Aplidin for treating multiple myeloma; and Zepzelca for treating patients with small cell lung cancer. The company also develops clinical-stage programs, including PM184 and PM14. In addition, it develops and markets diagnostics kits; and develops drugs with therapeutic activity based on reducing or silencing gene expression. Pharma Mar, S.A. was incorporated in 1986 and is based in Madrid, Spain.",
    "website": "http://www.pharmamar.com",
    "zipcode": "28770"
  },
  "PHMMF": {
    "city": "Madrid",
    "country": "Spain",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Biotechnology",
    "long_name": "Pharma Mar, S.A.",
    "market": "us_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "PHARMA MAR SA",
    "state": null,
    "summary": "Pharma Mar, S.A., a biopharmaceutical company, engages in the research, development, production, and commercialization of bio-active principles of marine origin for use in oncology in Spain, rest of Europe, and internationally. The company operates through three segments: Oncology, Diagnostics, and RNA interference. It develops and commercializes Yondelis for the treatment of soft tissue sarcomas and for ovarian cancer; Aplidin for treating multiple myeloma; and Zepzelca for treating patients with small cell lung cancer. The company also develops clinical-stage programs, including PM184 and PM14. In addition, it develops and markets diagnostics kits; and develops drugs with therapeutic activity based on reducing or silencing gene expression. Pharma Mar, S.A. was incorporated in 1986 and is based in Madrid, Spain.",
    "website": "http://www.pharmamar.com",
    "zipcode": "28770"
  },
  "PMRA.F": {
    "city": "Madrid",
    "country": "Spain",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Biotechnology",
    "long_name": "Pharma Mar, S.A.",
    "market": "dr_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "PHARMA MAR S.A. EO -,60",
    "state": null,
    "summary": "Pharma Mar, S.A., a biopharmaceutical company, engages in the research, development, production, and commercialization of bio-active principles of marine origin for use in oncology in Spain, rest of Europe, and internationally. The company operates through three segments: Oncology, Diagnostics, and RNA interference. It develops and commercializes Yondelis for the treatment of soft tissue sarcomas and for ovarian cancer; Aplidin for treating multiple myeloma; and Zepzelca for treating patients with small cell lung cancer. The company also develops clinical-stage programs, including PM184 and PM14. In addition, it develops and markets diagnostics kits; and develops drugs with therapeutic activity based on reducing or silencing gene expression. Pharma Mar, S.A. was incorporated in 1986 and is based in Madrid, Spain.",
    "website": "http://www.pharmamar.com",
    "zipcode": "28770"
  },
  "PRM.MC": {
    "city": "MÃ³stoles",
    "country": "Spain",
    "currency": "EUR",
    "exchange": "MCE",
    "industry": "Medical Instruments & Supplies",
    "long_name": "Prim, S.A.",
    "market": "es_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "PRIM, S.A.",
    "state": null,
    "summary": "Prim, S.A., through its subsidiaries, designs, manufactures, commercializes, installs, and maintains hospital and orthopaedic supplies and materials for physiotherapy, thalassotherapy, thermal therapy, rehabilitation, and geriatrics, as well as daily living aids in Spain and internationally. The company offers products for plastic, endo, E.N.T., and neuro surgeries; pain units; cardiovascular products; products for traumatology; and biomaterials. It also provides orthopedic products, such as ankle and knee supports, girdles, wristbands, hyperextension braces, prostheses and prosthetic components, incontinence and electro medical products, etc. through orthopedic supply shops, pharmacies, and cooperatives; and customized technical orthopedic products for people with disabilities. In addition, the company manufactures podiatry and orthotics products, as well as distributes technical aids, health care articles, and OTC products. Further, it engages in management of wellness projects, including spas, hotels, resorts, home, sports centers, and thalassotherapy facilities. Prim, S.A. was founded in 1870 and is based in MÃ³stoles, Spain.",
    "website": "http://www.prim.es",
    "zipcode": "28938"
  },
  "PUL.F": {
    "city": "Granada",
    "country": "Spain",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Biotechnology",
    "long_name": "Biosearch, S.A.",
    "market": "dr_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "BIOSEARCH S.A.INH. EO-,24",
    "state": null,
    "summary": "Biosearch, S.A., a biotechnology company, operates in pharmaceutical, nutraceutical, and functional food sectors worldwide. It offers a portfolio of approximately 200 products in lipids, probiotics, and botanical extracts. The company provides a range of probiotics isolated from human breast milk under the Hereditum brand for use in infant nutrition, gastrointestinal health, and immune system and prevention of infections. It also offers various eicosapentaenoic acid and docosahexaenoic acid rich ingredients under the Eupoly-3 name, which consists of oils, emulsions, and micro-encapsulated powder for functional foods, primarily dairy products, baby foods, medical foods, and food supplements. In addition, the company provides dry, fluid, glycerinated, and soft extracts under the Exxentia name. Biosearch, S.A. is headquartered in Granada, Spain.",
    "website": "http://www.biosearchlife.es",
    "zipcode": "18004"
  },
  "RJF.MC": {
    "city": "Barcelona",
    "country": "Spain",
    "currency": "EUR",
    "exchange": "MCE",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "Laboratorio Reig Jofre, S.A.",
    "market": "es_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "LABORATORIO REIG JOFRE, S.A.",
    "state": null,
    "summary": "Laboratorio Reig Jofre, S.A., a pharmaceutical company, researches, develops, manufactures, and markets pharmaceutical products and food supplements. The company offers prescription medicines, OTCs, medical devices, and cosmetics. Its products include pharmaceutical technologies products, such as antibiotics, and injectable and other products; specialty pharmacare products, which include skin, hair, and nail health, joint health and pain, women's health, respiratory/ENT, and pediatrics; and consumer healthcare products under the FortÃ© Pharma brand. The company also provides CDMO and CMO services. It sells its products directly in 7 countries and through business partners in approximately 70 countries. The company was founded in 1929 and is based in Sant Joan DespÃ­, Spain. Laboratorio Reig Jofre, S.A. is a subsidiary of Reig Jofre Investments SL.",
    "website": "http://www.reigjofre.com",
    "zipcode": "08970"
  },
  "ROVI.MC": {
    "city": "Madrid",
    "country": "Spain",
    "currency": "EUR",
    "exchange": "MCE",
    "industry": "Biotechnology",
    "long_name": "Laboratorios Farmaceuticos Rovi, S.A.",
    "market": "es_market",
    "market_cap": "Mid Cap",
    "sector": "Healthcare",
    "short_name": "LABORATORIOS FARMACEUTICOS ROVI",
    "state": null,
    "summary": "Laboratorios Farmaceuticos Rovi, S.A. engages in the research, development, production, and sale of pharmaceutical products in Spain, European Union, OECD countries, and internationally. The company distributes other products that are licensed from other laboratories. Its principal products include Hibor, a low-molecular-weight heparin to prevent and treat venous thromboembolic disease; Enoxaparin biosimilar Becat, a low-molecular-weight heparin; Neparvis to treat symptomatic chronic heart failure with reduced ejection in adult patients; Absorcol, Vytorin, and Orvatez to diet in patients with hypercholesterolemia; Hirobriz Breezhaler and Ulunar Breezhaler that are long-acting bronchodilators for the maintenance treatment of chronic obstructive pulmonary diseases; Volutsa for treatment of moderate to severe storage systems symptoms and voiding symptoms associated with benign prostatic hyperplasia in men who are not responding adequately to monotherapy treatment; and Medikinet and MedicebrÃ¡n to treat attention deficit hyperactivity disorder in children and teenagers. The company also markets various hospital products for imaging diagnosis, such as Iomeron and Iopamiro for computed tomography and intervention; Multihance and Prohance for magnetic resonance imaging; Sonovue for ultrasounds; and EmpowerCTA+, EmpowerMR, and CT ExprÃ¨s that are contrast injection systems and compatible disposable material. It provides non-prescription pharmaceutical products; and contract-manufacturing services to other companies for a range of pharmaceutical forms, including prefilled syringes, vials, suppositories, tablets, hard capsules, and sachets. The company serves wholesalers, doctors, nursing staff, pharmacists, and patients. It has a collaboration with Moderna, Inc. for manufacturing mRNA COVID-19 vaccine candidate. The company was incorporated in 1946 and is headquartered in Madrid, Spain. Laboratorios FarmaceÃºticos Rovi, S.A. is a subsidiary of Norbel Inversiones, S.L.",
    "website": "http://www.rovi.es",
    "zipcode": "28223"
  },
  "ZENO": {
    "city": "Valencia",
    "country": "Spain",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Diagnostics & Research",
    "long_name": "Zenosense, Inc.",
    "market": "us_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "ZENOSENSE INC",
    "state": null,
    "summary": "Zenosense, Inc., through its joint venture, MIDS Medical Ltd., operates as a healthcare technology company. It develops MIDS Cardiac, a hand-held point of care cardiac diagnostic device targeting cardiac markers for the diagnosis of heart attack and cardiac related illnesses. The company was formerly known as Braeden Valley Mines, Inc. and changed its name to Zenosense, Inc. in November 2013. Zenosense, Inc. was founded in 2008 and is headquartered in Valencia, Spain.",
    "website": "http://www.zenosense.com",
    "zipcode": "46015"
  }
}
